Category:VildagliptinVildagliptinVildagliptinVildagliptinaVildagliptineVildagliptin%E3%83%93%E3%83%AB%E3%83%80%E3%82%B0%E3%83%AA%E3%83%97%E3%83%81%E3%83%B3VildagliptineVildagliptina%D0%92%D0%B8%D0%BB%D0%B4%D0%B0%D0%B3%D0%BB%D0%B8%D0%BF%D1%82%D0%B8%D0%BDVildagliptinVildagliptinQ421042%E7%BB%B4%E6%A0%BC%E5%88%97%E6%B1%80
about
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal InsufficiencyAssessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 DiabetesVildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With MetforminSafety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese VolunteersTo Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesEffect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and MetforminDPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 DiabetesEffect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) TherapyStudy of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsDoes Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional StudyEfficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 DiabetesEfficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 DiabetesVildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 DiabetesVildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 DiabetesEfficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 DiabetesEfficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 DiabetesEffect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin MonotherapyEvaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes MellitusEfficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminThe Swiss Glucose Variability StudyCompare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 DiabetesGlucose Control in Pre-Diabetic Renal Transplant PatientsVildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 DiabetesStudy to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 DiabetesA Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsPhase 4 Study in the Elderly Patients With T2DMSafety and Efficacy of Galvus as add-on Therapy to Metformin Plus GlimepirideEfficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 DiabetesVildagliptin on Gastric AccommodationVildagliptin Versus Dapagliflozin on GlucagonPrognostic Predictors of Response to Hypoglycemic TherapyClinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DMThe DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder PatientsThe DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients
P4844
Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress/NF-κB PathwayParaganglioma presenting as stress cardiomyopathy: case report and literature reviewPancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study
P921
Q61914334-12297AB1-FE4E-475E-BEC5-721A93E4C1D8Q61915553-7EE09F0A-4EC2-4CF2-8D6D-7FE7E0C4C0E9Q61917623-0B03ACB7-2B0C-45FE-8DD3-5C62E42E699EQ61922029-3AC9B75A-D548-4407-9EC8-C32F135EC364Q61933775-287B1609-BE01-450A-8E43-AC387AE5CAE7Q61936246-1FEE8689-8C6E-4A79-8FDE-6607C0272EC8Q61955455-919F2F57-C4AC-456F-987D-28177C98DA1BQ61967136-91B64AFB-4E73-4AD7-A077-060586AC161CQ61969155-E2365A36-19A4-45B4-8024-91162AF37C26Q61975951-43CCAAB4-F82A-4B7B-9829-2D5D66AE20D1Q61981525-121FBFD2-B22D-4BFC-823C-5F7448245A00Q62105278-3900D405-2FDB-42E8-88CA-A62224873D21Q62105712-07AB887F-ACFA-4E78-A51F-8464C4653190Q62106259-0903C4FD-9CEA-46A5-84C6-8759DA4A11D0Q62106285-9F6A16B0-C493-4D12-922D-CC8F75C67B73Q62106534-C339AD2C-78B7-4339-9C4C-504CAAE16011Q63315747-86184B66-A85C-42DF-809B-BB312367B22BQ63317209-AABCB211-2C5A-47B9-BE8E-3775D44D8F0DQ63318706-01C88085-5BDE-4FCC-9A6D-63D6117AE24FQ63320137-DC159A79-819F-4B21-B3AF-A985867BF24DQ63321040-F092DC56-00EA-474A-853A-4A3FD3420671Q63321056-432865E3-7903-492E-866E-BDF4E3C94562Q63335190-B04AF476-F4B3-42CC-A1BD-3AFA7C97EBEAQ63336141-C78089AA-E6EA-4CEF-BE4A-4F8C618FE78CQ63336458-FB2A8C5C-98D3-4BFE-A31A-7EE4F299E452Q63336811-AB77990C-BD59-4B96-A7BE-68C34A7D87B4Q63340149-18E23A9F-63C0-46C6-A058-804F0D4F4D41Q63340433-5F518F15-28D0-404E-A3C5-357A9D2D593EQ63340901-CE689268-7B8E-4A0A-9932-39D1BB9F91D6Q63399120-BF40AE94-392B-407C-AF87-C20A47992653Q63399122-D481DB46-FD9C-400F-A231-EF0686F372B9Q63573596-D6AC3681-5675-4E8A-8523-EC3F622B6811Q63585005-C895232C-201F-42BD-B131-BBB936B814CCQ63587026-42C3CC81-3ECB-4EAF-9ABF-E6BD0F2C4170Q96056037-EDB568DE-1C9D-4D50-8225-6D41CF75ADC7Q96056038-93FDB2F2-3992-4071-BDAB-432F3A0991BE
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Vildagliptin
@de
Vildagliptin
@sh
Vildagliptin
@sr
Vildagliptina
@es
Vildagliptine
@nl
vildagliptin
@en
vildagliptin
@it
vildagliptin
@tr
vildagliptina
@pt
vildagliptine
@fr
type
label
Vildagliptin
@de
Vildagliptin
@sh
Vildagliptin
@sr
Vildagliptina
@es
Vildagliptine
@nl
vildagliptin
@en
vildagliptin
@it
vildagliptin
@tr
vildagliptina
@pt
vildagliptine
@fr
altLabel
274901-16-5
@fr
C17H25N3O2
@fr
EQUA
@en
Eucreas
@de
Galvus
@de
Galvus
@en
Galvus
@nl
Galvus®
@en
Jalra
@en
LAF-237
@en
prefLabel
Vildagliptin
@de
Vildagliptin
@sh
Vildagliptin
@sr
Vildagliptina
@es
Vildagliptine
@nl
vildagliptin
@en
vildagliptin
@it
vildagliptin
@tr
vildagliptina
@pt
vildagliptine
@fr